In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1420-1427

  Wiskirchen, Dora E ^a   Koomanachai, Pornpan ^a,b   Nicasio, Anthony M ^a   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; MEROPENEM; RIFAMPICIN; TIGECYCLINE;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG MEGADOSE; EPITHELIUM; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; THIENAMYCINS;

EID: 79953222596     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01253-10     Document Type: Article

References (47)

1. Acocella, G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
2. Allegranzi, B., et al. 2000. Concentrations of single-dose meropenem (1g iv) in bronchoalveolar lavage and epithelial lining fluid. J. Antimicrob. Chemother. 46:319-322.
3. AstraZeneca. 2009. Merrem I.V. (meropenem for injection) product information. AstraZeneca, Wilmington, DE.
4. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
5. Bouchillon, S. K., et al. 2005. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program: 2004). Diagn. Microbiol. Infect. Dis. 52:173-179.
6. Bradford, P. A., et al. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
7. Bratu, S., et al. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City. Arch. Intern. Med. 165:1430-1435.
8. Bratu, S., et al. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132.
9. Bulik, C. C., et al. 2010. Comparative activity of human simulated, high-dose, prolonged infusion of meropenem against Klebsiella producing the KPC carbapenamase versus Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54:804-810.
10. Castanheira, M., H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β- lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother. 52:570-573.
11. Cha, R. 2008. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Pharmacotherapy 28:295-300.
12. Conte, J. E., J. A. Golden, M. G. Kelly, and E. Zurlinden. 2005. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25:523-529.
13. Conte, J. E., J. A. Golden, J. E. Kipps, E. T. Lin, and E. Zurlinden. 2004. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 43:395-404.
14. Crandon, J. L., A. Kim, and D. P. Nicolau. 2009. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J. Antimicrob. Chemother. 64:837-839.
15. Daly, M. W., D. J. Riddle, N. A. Ledeboer, W. M. Dunne, and D. J. Ritchie. 2007. Tigecycline for the treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 27:1052-1057.
16. den Hollander, J. G., A. M. Horrevorts, M. L. van Goor, H. A. Verbrugh, and J. W. Mouton. 1997. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 41:95-100.
17. DeRyke, C. A., X. Du, and D. P. Nicolau. 2006. Evaluation of bacterial kill when modeling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 58:601-609.
18. Drusano, G. L., et al. 2004. Pharmacokinetics and penetration of meropenem into epithelial lining fluid in patients with ventilator-associated pneumonia, abstr. A-15. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
19. Elkhaïli, H., et al. 1996. High-performance liquid chromatographic assay for meropenem in serum. J. Chromatogr. B Biomed. Appl. 686:19-26.
20. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
21. Gasink, L. B., P. H. Edelstein, E. Lautenbach, M. Synnestvedt, and N. O. Fishman. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 30:1180-1185.
22. Goutelle, S., et al. 2009. Population modeling and Monte Carlo simulation study of the pharmacokinetics and anti-tuberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53:2974-2981.
23. Kuti, J. L., P. K. Dandekar, C. H. Nightingale, and D. P. Nicolau. 2003. Use of a Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43:1116-1123.
24. Landman, D., et al. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J. Antimicrob. Chemother. 60:78-82.
25. Li, C., J. L. Kuti, C. H. Nightingale, and D. P. Nicolau. 2006. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46:1171-1178.
26. Li, C., C. A. Sutherland, C. H. Nightingale, and D. P. Nicolau. 2004. Quantitation of tigecycline, a novel glycylcycline [corrected], by liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 811:225-229. (Pubitemid 39446769)
27. Maltezou, H. C., et al. 2009. Outbreak of infections due to KPC-2 producing Klebsiella pneumoniae in a hospital in Crete (Greece). J. Infect. 58:213-219.
28. Marchaim, D., S. Navon-Venzia, M. J. Schwaber, and Y. Carmeli. 2008. Isolation of imipenem-resistant Enterobacter species; emergence of KPC-carbapenemase, molecular characterization, epidemiology and outcomes. Antimicrob. Agents Chemother. 52:1413-1418.
29. Moland, E. S., et al. 2008. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob. Agents Chemother. 52:2940-2942.
30. Montero, A., et al. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 56:1085-1091.
31. Munoz-Price, L. S., and J. P. Quinn. 2009. The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin. Infect. Dis. 49:1739-1741.
32. Nicasio, A. M., J. L. Crandon, and D. P. Nicolau. 2009. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:2756-2761.
33. Nordmann, P., G. G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
34. Norskov-Lauritsen, N., H. Marchandin, and M. J. Dowzicky. 2009. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int. J. Antimicrob. Agents 34:121-130.
35. Pachon-Ibanez, M. E., F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, and A. Pascual. 2006. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia model, using rifampicin associated with imipenem or sulbactam. J. Antimicrob. Chemother. 58:689-692.
36. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
37. Pournaras, S., et al. 2010. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J. Clin. Microbiol. 48:2601-2604.
38. Prinipe, L., S. D'Arezzo, A. Capone, N. Petrosillo, and P. Visca. 2009. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 8:18.
39. Rubino, C. M., et al. 2007. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob. Agents Chemother. 51:4085-4089.
40. Saballs, M., et al. 2006. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58:697-700.
41. Sakka, S. G., et al. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob. Agents Chemother. 51:3304-3310.
42. Scheetz, M. H., et al. 2007. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:1621-1626.
43. Tisdale, J. E., M. T. Pasko, and J. M. Mylotte. 1989. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. Antimicrob. Agents Chemother. 33:1500-1505.
44. Van Wart, S. A., et al. 2006. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob. Agents Chemother. 50:3701-3707.
45. Weisenberg, S. A., D. J. Morgan, R. Espinal-Witter, and D. H. Larone. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64:233-235.
46. Yigit, H., et al. 2001. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161.
47. Zinner, S. H., J. Blaser, B. B. Stone, and M. C. Groner. 1985. Use of an in-vitro kinetic model to study antibiotic combinations. J. Antimicrob. Chemother. 15(Suppl. A):221-226.